Areas of activity

Therapeutic areas

We focus our activity on three areas of indication:


In haematology, Biotest’s plasma protein products are used above all in the prophylaxis and acute treatment of haemophilia A and haemophilia B, a blood coagulation disorder.

When people are afflicted with haemophilia, their bodies are unable to stop bleeding on their own. Even small external or internal injuries can have serious consequences; in extreme cases, without proper treatment, patients can bleed to death.

In prophylaxis, those affected receive regular injections of the clotting factor (every two to three days) to prevent haemorrhaging from even starting. Aside from regular medical and injection appointments, these patients can lead an essentially normal life without impairment by the condition. In case of acute hemorrhaging, factor VIII or factor IX preparations are used to stop the bleeding. 
This is described in more detail under “Research and development”. 

Clinical immunology

Biotest develops and produces various immunoglobulins in clinical immunology. They are used in the treatment and prophylaxis of disorders of the immune system, which are either inherited or acquired (e.g. through infection or other diseases). In simple terms, immunoglobulins prevent a virus or pathogen from spreading through the body.

Biotest has particular competence with hyperimmunoglobulins used in specific indications. One example is hepatitis B immunoglobulins. They are administered above all before, during and directly after liver transplants due to hepatitis B infection. This is described in more detail under “Research and development”.

Intensive care medicine

In intensive care and emergency medicine, plasma proteins from Biotest are used for example to correct for loss of blood volume and protein which can occur after serious injuries or burns. Another important therapeutic indication is severe bacterial infections (sepsis) or severe lung infections. In this area in particular, special immunoglobulin preparations such as Pentaglobin® or the Trimodulin which is still under development, directly save patients´ lives.